KRAS and malignant colon neoplasm: Chong et al. analyzed the publicly available proteomic data from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) colon cancer database, and demonstrated that tumors with WT KRAS exhibit a more active immune microenvironment, characterized by the enrichment of immune-related markers such as CD177, MMP1, and ARG1, suggesting a potentially better responsiveness to immunotherapies [23].